Sienna Senior Living Inc.

OTCPK:LWSC.F Stock Report

Market Cap: US$995.0m

Sienna Senior Living Valuation

Is LWSC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LWSC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LWSC.F ($12.1) is trading above our estimate of fair value ($0.35)

Significantly Below Fair Value: LWSC.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LWSC.F?

Key metric: As LWSC.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LWSC.F. This is calculated by dividing LWSC.F's market cap by their current earnings.
What is LWSC.F's PE Ratio?
PE Ratio44.9x
EarningsCA$30.98m
Market CapCA$1.39b

Price to Earnings Ratio vs Peers

How does LWSC.F's PE Ratio compare to its peers?

The above table shows the PE ratio for LWSC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.3x
USPH U.S. Physical Therapy
104.7x29.4%US$1.5b
NHC National HealthCare
15.7xn/aUS$2.0b
ARDT Ardent Health Partners
24.6x38.5%US$2.3b
CON Concentra Group Holdings Parent
16.1x4.0%US$2.8b
LWSC.F Sienna Senior Living
44.9xn/aUS$1.4b

Price-To-Earnings vs Peers: LWSC.F is expensive based on its Price-To-Earnings Ratio (44.9x) compared to the peer average (40.3x).

Price to Earnings Ratio vs Industry

How does LWSC.F's PE Ratio compare vs other companies in the US Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NEUE NeueHealth
1.5xn/aUS$41.27m
IDXG Interpace Biosciences
2.4xn/aUS$11.72m
FZMD Fuse Medical
1.1xn/aUS$4.57m
No more companies available in this PE range
LWSC.F 44.9xIndustry Avg. 24.6xNo. of Companies11PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LWSC.F is expensive based on its Price-To-Earnings Ratio (44.9x) compared to the US Healthcare industry average (24.6x).

Price to Earnings Ratio vs Fair Ratio

What is LWSC.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LWSC.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LWSC.F's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LWSC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$12.10
US$13.55
+11.9%
3.8%US$14.31US$12.87n/a8
Nov ’25US$12.53
US$13.05
+4.1%
6.6%US$14.40US$11.88n/a8
Oct ’25US$12.43
US$12.77
+2.7%
2.6%US$13.35US$12.24n/a7
Sep ’25US$11.31
US$12.77
+12.9%
2.6%US$13.35US$12.24n/a7
Aug ’25US$11.23
US$11.92
+6.2%
2.5%US$12.34US$11.61n/a7
Jul ’25US$9.93
US$12.00
+20.9%
2.3%US$12.49US$11.76n/a6
Jun ’25US$10.45
US$12.00
+14.9%
2.3%US$12.49US$11.76n/a6
May ’25US$9.76
US$10.60
+8.6%
4.0%US$11.33US$10.24n/a6
Apr ’25US$9.67
US$10.51
+8.7%
2.8%US$11.02US$10.29n/a5
Mar ’25US$9.80
US$10.51
+7.3%
1.7%US$10.74US$10.37n/a5
Feb ’25US$8.93
US$10.00
+12.0%
4.1%US$10.50US$9.37n/a6
Jan ’25US$8.64
US$10.00
+15.8%
4.1%US$10.50US$9.37n/a6
Dec ’24US$8.10
US$9.59
+18.4%
3.6%US$10.20US$9.11n/a6
Nov ’24US$7.36
US$9.82
+33.4%
3.3%US$10.12US$9.40US$12.536
Oct ’24US$8.01
US$10.16
+26.8%
2.7%US$10.37US$9.63US$12.437
Sep ’24US$8.71
US$10.16
+16.7%
2.7%US$10.37US$9.63US$11.317
Aug ’24US$8.69
US$10.18
+17.1%
4.2%US$10.61US$9.48US$11.237
Jul ’24US$8.67
US$10.04
+15.8%
5.1%US$11.03US$9.56US$9.937
Jun ’24US$8.36
US$10.04
+20.0%
5.1%US$11.03US$9.56US$10.457
May ’24US$8.09
US$10.04
+24.1%
5.1%US$11.03US$9.56US$9.767
Apr ’24US$7.81
US$10.04
+28.5%
5.1%US$11.03US$9.56US$9.677
Mar ’24US$8.73
US$10.16
+16.3%
6.1%US$11.05US$9.58US$9.807
Feb ’24US$9.00
US$10.77
+19.7%
5.0%US$11.95US$10.45US$8.937
Jan ’24n/a
US$10.78
0%
4.9%US$11.89US$10.41US$8.648
Dec ’23US$8.58
US$10.78
+25.6%
4.9%US$11.89US$10.41US$8.108
Nov ’23US$8.67
US$11.31
+30.5%
5.1%US$11.98US$10.32US$7.368

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

7D

18.8%

1Y

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

16.2%

1Y

99.5%